This hypothesis is supported by the evidence that CDX2 silencing interferes with the capacity of 5-ASA, a β-catenin inhibitor with anti-CRC chemoprevention activity, to upregulate MUCDHL expression. The gene discussed is CDHR5; the disease is colorectal carcinoma.